Cargando…

Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy

Treatment of cancer with EGFR inhibitors is limited by on-target skin toxicities induced by inhibition of the MAPK pathway. BRAF inhibitors are known to paradoxically activate the MAPK downstream of EGFR, which we confirmed using human skin keratinocytes. We then conducted a phase I clinical trial t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lacouture, Mario E., Wainberg, Zev A., Patel, Anisha B., Anadkat, Milan J., Stemmer, Salomon M., Shacham-Shmueli, Einat, Medina, Egmidio, Zelinger, Galit, Shelach, Noa, Ribas, Antoni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2021
Materias:	Research Brief
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418997/ https://www.ncbi.nlm.nih.gov/pubmed/33910927 http://dx.doi.org/10.1158/2159-8290.CD-20-1847

Ejemplares similares

Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review
por: Lacouture, Mario E., et al.
Publicado: (2017)

Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
por: Lacouture, Mario E., et al.
Publicado: (2011)

Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines
por: Lacouture, Mario E., et al.
Publicado: (2020)

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
por: Lassen, Amanda, et al.
Publicado: (2014)

Dermatologic events from EGFR inhibitors: the issue of the missing patient voice
por: Tischer, Bernd, et al.
Publicado: (2016)

Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors
por: Xu, Ting, et al.
Publicado: (2022)

Epigenetic Changes of EGFR play an important role in BRAF inhibitor Resistant Cutaneous Melanomas
por: Wang, Jinhua, et al.
Publicado: (2014)

Spatial profiling reveals association between WNT pathway activation and T-cell exclusion in acquired resistance of synovial sarcoma to NY-ESO-1 transgenic T-cell therapy
por: Campbell, Katie M, et al.
Publicado: (2022)

BRAF inhibitors in clinical oncology
por: Morris, Van, et al.
Publicado: (2013)

Role of PD-1 Inhibitors in the Treatment of Esophagogastric Adenocarcinoma: Patient Selection and Reported Outcomes
por: Epistola, Raisa, et al.
Publicado: (2023)

BRAF, MEK, and EGFR Triplet Inhibitors as Salvage Therapy in BRAF-Mutated Metastatic Colorectal Cancer—A Case Series Study Target Therapy of BRAF-Mutated mCRC
por: Yeh, Jen-Hao, et al.
Publicado: (2021)

Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors
por: Escuin-Ordinas, Helena, et al.
Publicado: (2016)

Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer
por: Aboubakar Nana, Frank, et al.
Publicado: (2021)

Complete response with fluorouracil and irinotecan with a BRAF(V600E) and EGFR inhibitor in BRAF-mutated metastatic colorectal cancer: a case report
por: Wang, Zhan, et al.
Publicado: (2019)

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
por: Atefi, Mohammad, et al.
Publicado: (2011)

ErbB3 plays a key role in the early phase of establishment of resistance to BRAF and/or MEK inhibitors
por: Fattore, Luigi, et al.
Publicado: (2015)

BRAF Inhibitor Resistance Confers Increased Sensitivity to Mitotic Inhibitors
por: Misek, Sean A., et al.
Publicado: (2022)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

Identification of synthetic chemosensitivity genes paired with BRAF for BRAF/MAPK inhibitors
por: Lee, Kye Hwa, et al.
Publicado: (2020)

Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma
por: Di Stefano, Anna Luisa, et al.
Publicado: (2020)

Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis
por: Stemmer, Amos, et al.
Publicado: (2020)

Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects
por: Escuin-Ordinas, Helena, et al.
Publicado: (2021)

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
por: Wong, Deborah JL, et al.
Publicado: (2014)

Metastasis Initiation Precedes Detection of Primary Cancer—Analysis of Metastasis Growth in vivo in a Colorectal Cancer Test Case
por: Hochman, Gili, et al.
Publicado: (2020)

The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study
por: Tietze, Julia K., et al.
Publicado: (2018)

Lessons from clinical trials on triple combination of immune checkpoint inhibitors and BRAF/MEK inhibitors in BRAF-mutant melanoma
por: Maeda, Takuya, et al.
Publicado: (2023)

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
por: Poulikakos, Poulikos I., et al.
Publicado: (2011)

Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors
por: Dolinsek, Tanja, et al.
Publicado: (2016)

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
por: Wong, Deborah JL, et al.
Publicado: (2015)

Ubiquitination and adaptive responses to BRAF inhibitors in Melanoma
por: Saei, Azad, et al.
Publicado: (2018)

Inhibitors of BRAF dimers using an allosteric site
por: Cotto-Rios, Xiomaris M., et al.
Publicado: (2020)

BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions
por: Proietti, Ilaria, et al.
Publicado: (2020)

BRAF mutation and its inhibitors in sarcoma treatment
por: Liu, Haotian, et al.
Publicado: (2020)

The multifaceted anti-cancer effects of BRAF-inhibitors
por: Croce, Laura, et al.
Publicado: (2019)

The impact of overall radiotherapy treatment time and delay in initiation of radiotherapy on local control and distant metastases in gastric cancer
por: Soyfer, Viacheslav, et al.
Publicado: (2014)

Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
por: Nanjo, Shigeki, et al.
Publicado: (2013)

Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth
por: Sweetlove, Melanie, et al.
Publicado: (2015)

Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment
por: Eliakim-Raz, Noa, et al.
Publicado: (2021)

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i2enlcub1nk36nklfbs0thtdkt